NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee A meeting minutes

**Minutes:** Confirmed

**Date:** Tuesday 13th August

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr James Fotheringham (Chair) Present for all items
2. Steve O’Brien (Chair for Topic 1) Items 1.1 to 4.2.2
3. Alan Thomas Present for all items
4. Ana Duarte Present for all items
5. Becky Pennington Present for all items
6. Dominic Pivonka Items 1.1 to 4.2.2
7. Dr Andrew Champion Present for all items
8. Dr Craig Buckley Present for all items
9. Dr Ian Bernstein Present for all items
10. Dr Mohit Sharma Present for all items
11. Dr Pratheeban Nambyiah Present for all items
12. Dr Ravi Ramessur Present for all items
13. Dr Steve Edwards Present for all items
14. Hugo Pedder Present for all items

Items 6.1 to 6.2.2

1. Jaqueline Tomlinson Present for all items
2. Mario Ganau Present for all items
3. Richard Ballerand Present for all items
4. Youssof Oskrochi Items 5.1 to 6.1.3

NICE staff (key players) present

Jacoline Bouvy, Programme Director / Acting Associate Director

Present 6.1 to 6.2.2

Janet Robertson, Associate Director Items 1.1 to 5.2.2

Jennifer Upton, Project Manager Present for all items

Summaya Mohammad, Heath Technology Assessment Adviser

Items 1.1 to 4.2.2

Rufaro Kausi, Heath Technology Assessment Analyst Items 1.1 to 4.2.2

Zoe Charles, Heath Technology Assessment Adviser Items 5.1 to 5.2.2

Rachel Williams, Heath Technology Assessment Analyst Items 5.1 to 5.2.2

Albany Chandler, Heath Technology Assessment Adviser Items 6.1 to 6.2.2

Emma Bajela, Heath Technology Assessment Analyst Items 6.1 to 6.2.2

External assessment group representatives present

Huiquin Yang, Kleijnen Systematic Reviews Items 1.1 to 4.1.3

Sabine Grimm, Kleijnen Systematic Reviews Items 1.1 to 4.1.3

Angela Boland, Liverpool Reviews and Implementation Group

Items 5.1 to 5.1.3

Nigel Fleeman, Liverpool Reviews and Implementation Group

Items 5.1 to 5.1.3

Ewen Cummins, Warwick Evidence Items 6.1 to 6.1.3

Lena Alkhudairy, Warwick Evidence Items 6.1 to 6.1.3

Clinical, Patient & NHS England experts present

James Richardson, NHS England Items 1.1 to 5.2.2

Ceri Steele, Patient Expert, nominated by Together Support Group

Items 1.1 to 4.1.3

David Chuter, Patient Expert, nominated by Together Support Group

Items 1.1 to 4.1.3

Martin Scott Brown, Clinical Expert, nominated by Astellas Pharma Ltd

Items 1.1 to 4.1.3

Sarah Le Brocq, Patient Expert, nominated by All About Obesity

Items 6.1 to 6.1.3

Matthew Capehorn, Clinical Expert, nominated by Eli Lilly and Company

Items 6.1 to 6.1.3

Dimitris Papamargatitis, Clinical Expert, nominated by Association for the Study of Obesity

Items 6.1 to 6.1.3

Paula Wilkinson, Commissioning Expert, Mid and South Essex ICB

Items 6.1 to 6.1.3

Sanjeev Patel, NHS England clinical lead Items 6.1 to 6.2.2

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Fiona MacPherson Smith, Min Ven Teo, G.J. Melendez-Torres, Justin Daniels, Patrick De Barr, Peter Baker-Gulliver and Radha Todd.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 9th July.

### Appraisal of Zolbetuximab with chemotherapy for untreated claudin 18.2-positive HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma [ID5123]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Astellas Pharma Ltd.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11316).
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Alan Thomas (lay), Ravi Ramessur (clinical) and Ana Duarte (cost).
  2. Part 2 – Closed session (company representatives, clinical and experts, external assessment group representatives were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11316>.

### Appraisal of Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [ID5100]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Pharma&.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10999).
     3. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by James Fotheringham.
  2. Part 2 – Closed session (company representatives, clinical experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10999>.

### Appraisal of Tirzepatide for managing overweight and obesity [ID6179]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Eli Lilly and Company
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11156).
     3. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by James Fotheringham.
  2. Part 2 –Closed session (company representatives, patient and clinical professional experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11156>.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee A will be held on Tuesday 10th September and will start promptly at 9am.